VMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Viemed Healthcare's EBIT per Share for the three months ended in Dec. 2024 was $0.16. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.43.
During the past 12 months, the average EBIT per Share Growth Rate of Viemed Healthcare was 5.70% per year. During the past 3 years, the average EBIT per Share Growth Rate was 9.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Viemed Healthcare's EBIT per Share or its related term are showing as below:
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Viemed Healthcare was 22.90% per year. The lowest was -14.90% per year. And the median was 7.30% per year.
Viemed Healthcare's EBIT for the three months ended in Dec. 2024 was $6.5 Mil.
The historical data trend for Viemed Healthcare's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viemed Healthcare Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
EBIT per Share | Get a 7-Day Free Trial |
![]() |
0.66 | 0.32 | 0.23 | 0.37 | 0.42 |
Viemed Healthcare Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EBIT per Share | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.13 | 0.06 | 0.08 | 0.14 | 0.16 |
EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.
Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.
Viemed Healthcare's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as
EBIT per Share | (A: Dec. 2024 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | 16.946 | / | 40.805 |
= | 0.42 |
Viemed Healthcare's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as
EBIT per Share | (Q: Dec. 2024 ) | ||
= | EBIT | / | Shares Outstanding (Diluted Average) | = | 6.452 | / | 41.114 |
= | 0.16 |
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viemed Healthcare (NAS:VMD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Thank you for viewing the detailed overview of Viemed Healthcare's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy Smokoff | director | 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508 |
Nitin Kaushal | director | 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508 |
Randy E. Dobbs | director | C/O VIEMED HEALTHCARE, INC, 625 E. KALISTE SALOOM RD, LAFAYETTE LA 70508 |
Sabrina Heltz | director | 625 E. KALISTE SALOOM ROAD, LAFAYETTE LA 70508 |
Jeremy Trahan | officer: Chief Legal Officer | 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508 |
Bruce D Greenstein | director | 901 HUGH WALLIS ROAD SOUTH, LAFAYETTE LA 70508 |
William Todd Zehnder | director, officer: Chief Operating Officer | 400 E. KALISTE SALOOM ROAD, SUITE 6000, LAFAYETTE LA 70508 |
Casey Hoyt | director, officer: Chief Executive Officer | 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508 |
Michael Moore | officer: President | 625 E. KALISTE SALOOM RD., LAFAYETTE LA 70508 |
Trae Fitzgerald | officer: Chief Financial Officer | 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508 |
William Frazier | director, officer: Chief Medical Officer | 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508 |
Jerome Cambre | officer: Vice President of Sales | 625 E KALISTE SALOOM RD, LAFAYETTE LA 70508 |
Ewell Patrick Eagan | officer: General Counsel | 625 E. KALISTE SALOOM ROAD, LAFAYETTE LA 70508 |
From GuruFocus
By GuruFocus News • 11-08-2024
By Marketwired • 10-22-2024
By GuruFocus Research • 03-08-2024
By Marketwired • 03-10-2025
By Marketwired • 07-24-2024
By GuruFocus News • 11-06-2024
By GuruFocus News • 03-21-2025
By Marketwired • 08-07-2024
By Marketwired • 11-06-2024
By GuruFocus Research • 05-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.